MedTrace Logo

Sexual Health and Rehabilitation eClinic (SHAReClinic)

NCT03396848 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2021-04-14

No results posted yet for this study

Summary

In addressing the need for effective post treatment support for men (and their partners) following treatment for prostate cancer, the investigators will employ an innovative SHAReClinic (Sexual health and Rehabilitation eClinic Program) that emphasizes: 1) a bio-medical component (erectile rehabilitation), focused on the long term return of erectile functioning firm enough for penetration with or without erectile agents/devices; and 2) a psychological component (intimacy maintenance), involving the maintenance or restoration of couples' intimacy. Through comparison research, the eClinic will be analyzed and made comparable in quality to the programs offered currently at leading institutions in major metropolitan areas, thus providing personalized, comprehensive cancer care to all Canadians.

Conditions

Interventions

OTHER

SHAReClinic

Online clinic with educational modules

Sponsors & Collaborators

  • Tom Baker Cancer Centre

    collaborator OTHER

  • Vancouver Coastal Health

    collaborator OTHER_GOV

  • Sunnybrook Health Sciences Centre

    collaborator OTHER

  • Nova Scotia Cancer Centre

    collaborator OTHER

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Andrew G Matthew, PhD · University Health Network, Toronto

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-23
Primary Completion
2019-04-30
Completion
2021-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03396848 on ClinicalTrials.gov